Intellikine, Inc. Company Profile
Intellikine is a private, clinical-stage company focused on the discovery and development of innovative small molecule drugs targeting the PI3K/mTOR pathway. Intellikine recently announced the start of a Phase I trial for INK128, a selective TORC1/2 inhibitor for oncology and is advancing INK1197, a PI3K-delta/gamma dual-selective inhibitor for the treatment of inflammatory and respiratory diseases. Other programs include PI3K-delta/gamma dual-selective inhibitors for oncology, PI3K-alpha/beta selective inhibitors for oncology, as well as other isoform-selective inhibitors. Intellikine has raised $41 million from an outstanding group of life science investors including Abingworth, Sofinnova Ventures, CMEA Capital, Novartis Venture Funds, U.S. Venture Partners, Biogen Idec and FinTech Global Capital. In addition, Intellikine has a commitment, subject to fulfillment of certain conditions, for another $22.5 million in equity financing from its current investors. For more information, please visit the company's website at www.intellikine.com.
News Articles
A “Restart” for Entrepreneurship Programs at UCSF
The University of California, San Francisco, is no stranger to commercialization of academic research. UCSF professor Herbert Boyer co-founded Genentech, the company that arguably kicked off the entir...
Infinity, Takeda amend PI3K deal
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) amended a 2010 deal on Monday under which Infinity has exclusive, worldwide rights to develop and commercial...
Araxes Pharma Enters Into Cancer Drug Discovery and Development Agreement With Janssen Biotech
SAN DIEGO, Calif., Feb. 27, 2013 /PRNewswire/ -- Araxes Pharma LLC announced today it has entered into an exclusive arrangement with Janssen Biotech, Inc. to develop first-in-class therape...
Araxes debuts with Janssen cancer deal
Newco Araxes Pharma LLC (San Diego, Calif.) partnered with the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) to discover and develop therapeutics against an undisclosed target to tre...
Hark back to the golden days of JP Morgan, all of two months ago. The sun was shining, the cable cars were whirring, and CMEA Capital was touting its long-awaited CMEA 8 fund. It even had posted Web...
Australian-based drug and development company Agenix Limited (ASX:AGX) today announced the appointment of Dr Paul Resnick as business advisor. Dr Resnick will initially focus on t...
Drugs and Medications
None
PubMed Articles
Deal watch: Infinity and Intellikine to develop oral PI3K inhibitors for inflammatory diseases.
Clinical Trials
None
Companies
Intellikine is a private, clinical-stage company focused on the discovery and development of innovative small molecule drugs targeting the PI3K/mTOR pathway. Intellikine recently announced the start...
More Information about "Intellikine, Inc." on BioPortfolio
We have published hundreds of Intellikine, Inc. news stories on BioPortfolio along with dozens of Intellikine, Inc. Clinical Trials and PubMed Articles about Intellikine, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Intellikine, Inc. Companies in our database. You can also find out about relevant Intellikine, Inc. Drugs and Medications on this site too.
